-
Even more powerful!
Time of Update: 2021-12-07
In this investment, up to US$150 million will be used to develop and commercialize obecabtagene autoleucel (Obe-cel), a targeted CD19 CAR-T cell therapy for the treatment of acute lymphoblastic leukemia .
-
[Lymphoma micro course 2021ASH first look] After IRV, different courses of treatment are followed according to risk stratification. R-HyperCVAD/MTX is used for young newly-treated MCL patients
Time of Update: 2021-12-07
Therefore, they designed the Window 2 study to evaluate the use of IRV in young newly-treated MCL patients after the use of IRV according to risk stratification and sequential different courses of treatment R- HyperCVAD/MTX is used as a consolidation therapy for the safety and efficacy.
-
Express 61% of patients achieved complete remission!
Time of Update: 2021-12-07
▎The content team editor of WuXi AppTec recently, PharmaEssentia announced that the US FDA has approved the long-acting interferon Besremi (ropeginterferonα-2b-njft) to be marketed for the treatment of adult patients with polycythemia vera (PV) .
-
Professor Ming Hou: New exploration of multi-target combined therapy for immune thrombocytopenia (ITP)
Time of Update: 2021-12-07
Professor Ming Hou said that DXM combined with RTX treatment for newly treated ITP patients can achieve a higher remission rate without significantly increasing the incidence of AEs .
-
Peritransplantation treatment with rucotinib improves the prognosis of MF patients
Time of Update: 2021-12-07
Reviewing the MF patients who received rucotinib treatment until the day before the start of pretreatment, no significant delay in HSCT implantation, NRM, acute graft versus host disease (aGVHD) ) Or the incidence of chronic graft-versus-host disease (cGVHD) has not increased significantly, but studies have reported an increase in the reactivation rate of cytomegalovirus (CMV) [1].
-
Professor Hu Qun keeps pace with the times and adapts measures to local conditions. The new version of the Chinese Children’s ITP Guidelines has been released, and the standardized diagnosis and treatment of children’s ITP has gone further
Time of Update: 2021-12-07
In order to further improve the level of children's ITP diagnosis and treatment in China, experts in the field of children's blood have issued new guidelines that clarify the treatment goals: more than just To increase the platelet count, it is important to stop bleeding, reduce adverse drug reactions, and improve the quality of life of patients .
-
New Vision of Myeloma The treatment model and outcome of patients with newly diagnosed multiple myeloma that are not suitable for transplantation in the real world
Time of Update: 2021-12-06
A retrospective analysis published in Annals of Hematology in July 2021 evaluated the clinical and demographic characteristics of patients with newly diagnosed multiple myeloma (MM) and conventional treatment in the real world, from Spain, who are not suitable for transplantation, The treatment mode and outcome, the editor will take you to learn more about the research results .
-
Express first-line treatment of leukemia, precision therapy combination significantly prolongs the survival time of patients
Time of Update: 2021-12-06
▎The content team editor of WuXi AppTec recently announced that Daiichi Sankyo (Daiichi Sankyo) announced that the oral FLT3 inhibitor quizartinib will be combined with standard chemotherapy for the first-line treatment of 3 patients with acute myeloid leukemia (AML) with FLT3-ITD mutations.
-
Professor Xiaoling Cheng has strategies for the dose adjustment of Eltroipopag, and the precise treatment of children with ITP will benefit more
Time of Update: 2021-12-06
In a real-world study in China, Eltrombopag showed good efficacy and safety for ITP patients aged 1 year and above, and there was no significant difference in dosage between East Asian children and European and American children .
-
Myeloma New Vision's current management methods for high-risk multiple myeloma
Time of Update: 2021-12-06
High-risk MM patients need intensive treatment to maximize the depth of remission; progression-free survival (PFS) is significantly reduced, and the initial response cannot be maintained, and continuous treatment is required; high-risk MM patients have limited OS even with new treatment methods, and it is recommended to consider participating Risk-adaptive clinical trials .
-
Acatinib brings hope to patients with ibrutinib intolerance to R/R CLL
Time of Update: 2021-12-06
Based on this, some researchers have explored the efficacy and safety of acatinib in patients with R/R CLL who are intolerant to the treatment of ibrutinib and whose disease continues to be active .
-
Blood Yan Daoguang's team from Jinan University discovered a new potential therapeutic target for T cell leukemia
Time of Update: 2021-12-06
iNature estimates that there are 5 to 20 million human T-cell leukemia virus 1 (HTLV-1) infections worldwide, of which 3-5% of carriers progress to fatal adult T-cell leukemia (ATL), with a median survival time of 2 To 6 months .
-
Genxi Biologics' BCMA/CD19 dual-target CAR-T cell therapy GC012F for the treatment of multiple myeloma was granted orphan drug designation by the U.S. FDA
Time of Update: 2021-12-06
S. Food and Drug Administration (FDA) has granted it the orphan of the BCMA/CD19 dual-target CAR-T cell therapy developed based on the FasTCAR technology platform Drug qualification (ODD) for the treatment of multiple myeloma .
-
The role of Nature Cancer LILRB family member LILRB3 in the development of acute myeloid leukemia
Time of Update: 2021-12-06
1038/s43018-021-00262-0 Platemaker: Notes for reprinting on the 11th [Non-original article] The copyright of this article belongs to the author of the article.
-
2021 ASH Voice of China Professor Zhou Daobin's team new progress: the efficacy and safety of abutinib in patients with relapsed/refractory WM
Time of Update: 2021-12-06
The primary endpoint is the primary response rate (MRR) assessed by the IRC, and the primary and secondary endpoints are the investigator-assessed MRR, overall response rate (ORR), duration of primary response (DOMR), progression-free survival (PFS), overall survival Period (OS), changes in IgM levels, improvement in hemoglobin levels, and safety .
-
Chemotherapy combined with sorafenib may bring more benefits to young newly diagnosed AML patients
Time of Update: 2021-12-06
Based on this, the researchers further analyzed this study to explore the type and efficacy of second-line treatment for patients with relapse in the study, including the proportion and method of allogeneic stem cell transplantation (Allo-SCT), and the effect after the second complete remission (CR) Cumulative recurrence rate (CIR) and OS after the first recurrence .
-
Zhou Guangbiao/Chen Saijuan/Chen Jiangming found that thalidomide is effective for patients with transfusion-dependent β-thalassemia
Time of Update: 2021-12-06
19)" Patients with transfusion-dependent β-thalassemia: a randomized clinical trial" research paper, in this multi-center, randomized, double-blind phase 2 clinical trial, the study aims to determine the safety of thalidomide in TDT patients Sex and effectiveness .
-
Gene therapy for hemophilia A achieves long-term curative effect
Time of Update: 2021-12-06
AAV gene therapy for hemophilia A achieves long-term efficacy November 28, 2021, the New England Journal of Medicine (NEJM) published the long-term follow-up results of the Phase 1/2 clinical trial of hemophilia A gene therapy, 18 patients participated in the treatment In 16 patients, good treatment results were achieved, and bleeding symptoms were significantly reduced.
-
CRISPR technology continues to advance hematopoietic stem cell therapy, focusing on sickle cell disease treatment
Time of Update: 2021-12-06
New Coronary Antibody Therapeutics Receives Positive Opinion from CHMPMedMeng broke the news November 20, 2021/MedClub News/--Next-generation gene editing company Graphite Bio recently announced that its gene-edited autologous hematopoietic stem cell therapy GPH 101 The first patient has been included in a phase 1/2 clinical trial.
-
Express CRISPR gene editing and improvement, innovative CAR-T therapy was recognized by the FDA as an advanced therapy for regenerative medicine
Time of Update: 2021-12-05
"Reference: [1] CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies.
com/news-releases/news-release-details/crispr-therapeutics-announces-fda-regenerative-medicine-advanced[2] CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies.
